123 related articles for article (PubMed ID: 37897887)
1. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
[TBL] [Abstract][Full Text] [Related]
3. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.
Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY
Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
5. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
8. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis.
Xu YC; Chen KH; Liang ZG; Zhu XD
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1793-1802. PubMed ID: 36335249
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
[TBL] [Abstract][Full Text] [Related]
11. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.
Lyu Y; Ni M; Zhai R; Kong F; Du C; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2549-2557. PubMed ID: 33021689
[TBL] [Abstract][Full Text] [Related]
13. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).
Mi JL; Meng YL; Wu HL; Cao YL; Zhang B; Pan YF; Zhou YY; Fan JF; Liao SF; Qin XL; Yao DC; Jiang W
Strahlenther Onkol; 2020 Mar; 196(3):270-279. PubMed ID: 31748837
[TBL] [Abstract][Full Text] [Related]
15. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
16. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies.
Yang G; Huang J; Sun J; Wang L
Cancer Med; 2023 Oct; 12(19):19523-19529. PubMed ID: 37724570
[TBL] [Abstract][Full Text] [Related]
17. Whole-body hyperthermia combined with chemotherapy and intensity-modulated radiotherapy for treatment of advanced nasopharyngeal carcinoma: a retrospective study with propensity score matching.
Zheng N; Xu A; Lin X; Mo Z; Xie X; Huang Z; Liang Y; Cai Z; Tan J; Shao X
Int J Hyperthermia; 2021; 38(1):1304-1312. PubMed ID: 34468276
[TBL] [Abstract][Full Text] [Related]
18. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
19. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
